CEBPA and leukemia: R-2-Hydroxyglutarate (R-2-HG) can also inhibit FTO activity, thereby increasing the m6A RNA modification in R-2HG-sensitive leukemia cells, reducing the stability of MYC/CEBPA transcripts, and leading to the inhibition of related pathways.